| Literature DB >> 30655951 |
Mark E Schnute1, Stephen E Benoit1, Ingrid P Buchler1, Nicole Caspers2, Margaret L Grapperhaus3, Seungil Han2, Rajeev Hotchandani1, Nelson Huang1, Robert O Hughes1, Brian M Juba1, Kyung-Hee Kim1, Erica Liu1, Erin McCarthy1, Dean Messing1, Joy S Miyashiro1, Shashi Mohan1, Thomas N O'Connell2, Jeffrey F Ohren2, Mihir D Parikh2, Michelle Schmidt3, Shaun R Selness3, John R Springer1, Venkataraman Thanabal2, John I Trujillo2, Daniel P Walker3, Zhao-Kui Wan1, Jane M Withka2, Arthur J Wittwer3, Nancy L Wood1, Li Xing1, Christoph W Zapf1, John Douhan1.
Abstract
Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity. The cyanamide covalent mechanism with BTK was confirmed through enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.Entities:
Year: 2018 PMID: 30655951 PMCID: PMC6331194 DOI: 10.1021/acsmedchemlett.8b00461
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345